Abstract: The present innovation relates to a novel formulation capable of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the formulation is characterized in that it contains defibrotide in combination with at least one haematopoietic factor having the capacity to mobilize haematopoietic progenitors, preferably G-CSF. In one embodiment, the formulation includes two separately administrable formulations, one containing a haematopoietic factor having the capacity to mobilize haematopoietic progenitors and the other containing defibrotide. The formulation is effective to achieve an increase in the number of haematopoietic progenitor cells that is greater than an increase in the number of haematopoietic progenitor cells achieved by the haematopoietic factor alone.

Abstract: The present innovation relates to a novel formulation capable of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the formulation is characterized in that it contains defibrotide in combination with at least one haematopoietic factor having the capacity to mobilize haematopoietic progenitors, preferably G-CSF. In one embodiment, the formulation includes two separately administrable formulations, one containing a haematopoietic factor having the capacity to mobilize haematopoietic progenitors and the other containing defibrotide. The formulation is effective to achieve an increase in the number of haematopoietic progenitor cells that is greater than an increase in the number of haematopoietic progenitor cells achieved by the haematopoietic factor alone.

Abstract: The present innovation relates to a novel formulation capable of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the formulation is characterized in that it contains defibrotide in combination with at least one haematopoietic factor having the capacity to mobilize haematopoietic progenitors, preferably G-CSF. In one embodiment, the formulation includes two separately administrable formulations, one containing a haematopoietic factor having the capacity to mobilize haematopoietic progenitors and the other containing defibrotide. The formulation is effective to achieve an increase in the number of haematopoietic progenitor cells that is greater than an increase in the number of haematopoietic progenitor cells achieved by the haematopoietic factor alone.

Abstract: The present study has demonstrated that heparanase expression and activity was increased in human microvascular endothelial cells and rat kidney epithelial cells growing under hyperglycemia condition, as found in diabetic nephropathy disease. Oligotide was able to: —downregulate the heparanase gene expression; —downregulate the cell surface protein expression; —decrease the heparanase enzymatic activity. Since heparanase is a critical factor in maintaining glomerular basement membrane integrity and is elevated in renal diseases, as for instance diabetic nephropathies. Oligotide should be considered for the management of these diseases.

Abstract: The present innovation relates to a novel formulation capable of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the formulation is characterised in that it contains defibrotide in combination with at least one haematopoietic factor having the capacity to mobilise haematopoietic progenitors, preferably G-CSF. In one embodiment, the formulation includes two separately administrable formulations, one containing a haematopoietic factor having the capacity to mobilize haematopoietic progenitors and the other containing defibrotide. The formulation is effective to achieve an increase in the number of haematopoietic progenitor cells that is greater than an increase in the number of haematopoietic progenitor cells achieved by the haematopoietic factor alone.

Abstract: Method for determining the biological activity of defibrotide by a) bringing into contact defibrotide, plasmin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide.

Abstract: The use of defibrotide as an anti-tumour agent, alone or in combination with other active ingredients with anti-tumour action, is described.

Abstract: The present research is directed to the identification of non-peptidic inhibitors of cathepsin G characterised by high levels of selectivity and which can be efficaciously used in the treatment and prophylaxis of inflammatory occurrences and procoagulant conditions. The cathepsin G-inhibiting aptamers according to the invention consist of linear DNA or polynucleotide sequences having a chain length of at least 60 nucleotides and being substantially not subjected to undergo efficient base pairing.

Abstract: An enzymatic method for determining the biological activity of defibrotide is described. This method, which is based on the capacity of defibrotide to potentiate the enzymatic activity of plasmin, comprises the steps of: a) bringing into contact defibrotide, plasmin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product and b) measuring the amount of product formed at successive times.

Abstract: The invention relates to the use as medicaments, specifically as antiinflammatories, of complexes formed by cationic liposomes and polydeoxyribonucleotides having a molecular weight in the range 7,000-60,000 Da obtainable by depolymerization of nucleic acids, wherein in said complexes the polydeoxyribonucletoides are located on the outer surface of the liposome.

Abstract: A description is given of a method of increasing the amount of stem cells and progenitor cells in the peripheral blood of a mammal: the method is characterised by the administration of defibrotide in combination or in temporal proximity with at least one haematopoietic factor, (preferably G-CSF) having the capacity to mobilise haematopoietic progenitors.

Abstract: The invention relates to the use as medicaments, specifically as antiinflammatories, of complexes formed by cationic liposomes and polydeoxyribonucleotides having a molecular weight in the range 7,000-60,000 Da obtainable by depolymerization of nucleic acids, wherein in said complexes the polydeoxyribonucletoides are located on the outer surface of the liposome.

Abstract: Fucans with low molecular weight having anticoagulant, antithrombinic and antithrombotic activity.Fucan sulfates having molecular weight between 14000 and 29000 Dalton show a remarkable anticoagulant activity both in the global coagulation mechanism (APTT) and in the last phase of coagulation (antithrombinic activity). These compounds are useful also as antithrombotic drugs.

Abstract: The invention discloses new compositions of mesalazine in the form of aqueous suspensions, characterized in that they are more stable than those of the prior art. The compositions contain colloidal cellulose and one or more hydrophilic thickening agents.

Abstract: A pharmaceutical composition comprising a polydeoxyribonucleotide of random sequence formula is disclosed, andP.sub.v, (dAp).sub.w, (dGp).sub.x, (dTp).sub.y, (dCp).sub.zwhereinP.sub.v is 1-5 phosphoric radicals,(dAp).sub.w is 12-24 deoxyadenylic monomers,(dGp).sub.x is 10-20 deoxyguanylic monomers,(dTp).sub.y is 13-26 deoxythymidylic monomers, and(dCp).sub.z is 10-20 deoxycytidylic monomers;wherein the polydeoxyribonucleotide has:a homogenous anodic mobility in electrophoresis,an extinction coefficient E.sup.1%.sub.1 cm at 260.+-.1 nm=220.+-.10,an extinction coefficient E.sub.230 /E.sub.260 =0.45.+-.0.04,a molar extinction coefficient (referred to phosphorous), .epsilon.(P)=7750.+-.500,a rotary power ?.alpha.!.sup.20.degree..sub.D =53.degree..+-.6, anda reversible hyperchromicity as percent in native DNA h=15.+-.5, in combination with a pharmaceutically acceptable carrier or diluent. A method of treating or preventing a diabetic neuropathy using the polydeoxyribonucleotide is also shown.

Abstract: Polysaccharides and more in particular glycosaminoglycans, their mixtures, fractions and derivatives thereof are effective agents in the therapy of acute peripheral neuropathies of traumatic and ischemic origin and in the therapy of acute peripheral neuropathies of toxic origin.